TrialPanorama/Dataset huggingface dataset:
Please select the outcome measures that correspond to the clinical trial below.
Title: In-home Prevention of SA Risks for Native Teen Families
Brief Summary: The purpose of this study is to determine whether an in-home, paraprofessional-delivered family strengthening curriculum entitled Family Spirit is effective at increasing parental competence, improving maternal outcomes and improving childhood outcomes in a sample of at-risk teen mothers living in four Native American reservation communities. The effectiveness of the Family Spirit curriculum will be determined by comparing outcomes of mothers who receive the intervention plus assisted transportation to prenatal and well baby visits (called Optimal Standardized Care) to mothers who receive only Optimal Standardized Care. Outcomes will be assessed at multiple intervals over the course of a 39-month study period.


Options:
A: Reduction in SSB initiation and frequency among infants up to 12-months of age (12-months of age); Change in optimal complementary feeding and responsive parenting practices in mothers who receive FSN vs controls (3-months and 12-months of age); Change in SSB consumption among infants due to water insecurity (6-months of age)
B: Acceptability of the home-visiting program from the perspective of mothers enrolled (Baseline, 2-months postpartum, 6-months postpartum, 12-months postpartum); Retention in the home-visiting programs (2-months postpartum, 6-months postpartum, 12-months postpartum); Participant satisfaction (6-months postpartum, 12-months postpartum); Adherence (Study enrollment through study completion, an average of 1 year); Home visitor-participant relationship (2-months postpartum, 6-months postpartum, 12-months postpartum)
C: Child cognitive development, behavior, and health (At-risk sample: Up to 8 years; Not-at risk sample: Up to 2 years); Child social-emotional development (At-risk sample: Up to 6 years; Not-at risk sample: Up to 1 year); Child depression (At-risk sample: Up to 8 years; Not-at risk sample: Up to 2 years)
D: Increase in parental competence at nine intervals over 39 month study period (birth-3 year postpartum)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: In-home Prevention of SA Risks for Native Teen Families
Brief Summary: The purpose of this study is to determine whether an in-home, paraprofessional-delivered family strengthening curriculum entitled Family Spirit is effective at increasing parental competence, improving maternal outcomes and improving childhood outcomes in a sample of at-risk teen mothers living in four Native American reservation communities. The effectiveness of the Family Spirit curriculum will be determined by comparing outcomes of mothers who receive the intervention plus assisted transportation to prenatal and well baby visits (called Optimal Standardized Care) to mothers who receive only Optimal Standardized Care. Outcomes will be assessed at multiple intervals over the course of a 39-month study period.


Options:
A: 7-day Point Prevalence Smoking Abstinence at 8 Weeks (8 weeks); 7-day Point Prevalence Smoking Abstinence at 16 Weeks (16 Weeks); 7-day Point Prevalence Smoking Abstinence at 26 Weeks (26 Weeks)
B: Increase in parental competence at nine intervals over 39 month study period (birth-3 year postpartum)
C: Hamilton Depression Scale, Timeline Follow-back (substance measure) (18 months)
D: Evaluation of smoking cessation verified by expired air carbon monoxide (12 weeks after baseline)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: In-home Prevention of SA Risks for Native Teen Families
Brief Summary: The purpose of this study is to determine whether an in-home, paraprofessional-delivered family strengthening curriculum entitled Family Spirit is effective at increasing parental competence, improving maternal outcomes and improving childhood outcomes in a sample of at-risk teen mothers living in four Native American reservation communities. The effectiveness of the Family Spirit curriculum will be determined by comparing outcomes of mothers who receive the intervention plus assisted transportation to prenatal and well baby visits (called Optimal Standardized Care) to mothers who receive only Optimal Standardized Care. Outcomes will be assessed at multiple intervals over the course of a 39-month study period.


Options:
A: Time Line Follow Back and urine screen (Pre and post-treatment, 3 and 6 month follow-ups)
B: Diagnosis of mental health disorder (15 year follow-up)
C: Increase in parental competence at nine intervals over 39 month study period (birth-3 year postpartum)
D: Primary outcome variables include alcohol misuse and violent behaviors. (12-months)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Behavioral Interventions for Low Back Pain
Brief Summary: Low back pain is a very common problem and the most common cause of job-related disability. While some occurrences of low back pain disappear within a couple of days, other occurrences take much longer to resolve or lead to more serious conditions. The purpose of this study is to determine the effectiveness of two behavioral types of therapy in reducing future disability in people who are receiving physical therapy for low back pain and tend to fear and avoid pain.


Options:
A: Brief Pain Inventory Interference (Measured at Year 1); HSCL-20 Depression Severity (Measured at Year 1)
B: Pain intensity (Measured at Week 4 and Month 6); Pain-related disability (Measured at Week 4 and Month 6)
C: pain; disability; fatigue; psychological distress at post treatment and 6 month follow-up
D: Return-to-work=the proportion of patients who during 1-18 months regained a degree of work ability>0 for at least 30 days in succession. (18 months.)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Real-Time Support for Exercise Persistence in COPD
Brief Summary: The purpose of this exploratory study is to determine the feasibility, acceptability, and efficacy of an exercise persistence intervention for patients with chronic obstructive pulmonary disease (COPD) following pulmonary rehabilitation (PR).


Options:
A: Exercise behavior (3 & 6 Months)
B: walked in meters in the six minute walking test (6MWT) (Unlike walking meters of baseline and one year)
C: The benefits of resistance training during exacerbation of COPD on peripheral muscle strength during hospitalization (Will be evaluated on the second day of hospitalization, the day of hospital discharge (this time interval must be longer than five days))
D: Chronic Respiratory Disease Questionnaire (6, 12, and 18 months); 6-minute walk (6, 12, and 18 months)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Real-Time Support for Exercise Persistence in COPD
Brief Summary: The purpose of this exploratory study is to determine the feasibility, acceptability, and efficacy of an exercise persistence intervention for patients with chronic obstructive pulmonary disease (COPD) following pulmonary rehabilitation (PR).


Options:
A: Combined number of hospitalizations and emergency department presentations (Two years)
B: "Quality of care process" (one year)
C: Exercise behavior (3 & 6 Months)
D: Hospital Readmission (12 months)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Real-Time Support for Exercise Persistence in COPD
Brief Summary: The purpose of this exploratory study is to determine the feasibility, acceptability, and efficacy of an exercise persistence intervention for patients with chronic obstructive pulmonary disease (COPD) following pulmonary rehabilitation (PR).


Options:
A: Dyspnea; Exercise adherence and performance; Pulmonary exacerbations
B: disease-specific health-related quality of life (HRQoL) (two years)
C: Exercise behavior (3 & 6 Months)
D: The two primary outcomes are disease-specific quality of life assessed with the St. George's Respiratory Questionnaire (SGRQ) and the total number of exacerbations

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Real-Time Support for Exercise Persistence in COPD
Brief Summary: The purpose of this exploratory study is to determine the feasibility, acceptability, and efficacy of an exercise persistence intervention for patients with chronic obstructive pulmonary disease (COPD) following pulmonary rehabilitation (PR).


Options:
A: Time to Need for Inhaled or Intravenous (IV) Antipseudomonal Antibiotics (Day 0 to Day 84 (end of study))
B: Daily step count (90 days)
C: Change in lung functions determined at 0,3,6,12,18,24 months; Change in exercise capacity determined at 0,3,6,12,18,24; months; Change in physical activity determined at 0,3,6,12,18,24 months; Change in quality of life determined at 0,3,6,12,18,24 months
D: Exercise behavior (3 & 6 Months)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Real-Time Support for Exercise Persistence in COPD
Brief Summary: The purpose of this exploratory study is to determine the feasibility, acceptability, and efficacy of an exercise persistence intervention for patients with chronic obstructive pulmonary disease (COPD) following pulmonary rehabilitation (PR).


Options:
A: Exercise behavior (3 & 6 Months)
B: Clinical COPD Questionnaire (CCQ) (Up to 3 weeks); Timed Up & Go test (TUG) (Up to 3 weeks); The five time sit to stand test (FTSST) (Up to 3 weeks); Patients' falls during training (Up to 3 weeks); Need for acute contact to the general practitioner (Up to 3 weeks); Patient subjective perception (Up to 3 weeks); Costs per patient participating in the telemedicine rehabilitation (Up to 3 weeks); Reimbursement to the hospital (Up to 3 weeks); Focus Group interview (Up to 3 weeks)
C: Number of hospitalizations due to exacerbation of COPD avoided (1 year)
D: Improvement in physical activity (1 month)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Real-Time Support for Exercise Persistence in COPD
Brief Summary: The purpose of this exploratory study is to determine the feasibility, acceptability, and efficacy of an exercise persistence intervention for patients with chronic obstructive pulmonary disease (COPD) following pulmonary rehabilitation (PR).


Options:
A: Dyspnea with ADL (3, 6, and 12 months); Exercise and functional performance (3, 6, and 12 months); Exercise adherence (3, 6, and 12 months); Acute COPD exacerbations (3, 6, and 12 months)
B: Self-Reported Respiratory-Specific Quality of Life (four months from randomization); Self-Reported Respiratory-Specific Quality of Life (twelve months from randomization)
C: Dyspnea; Exercise adherence and performance; Pulmonary exacerbations
D: Exercise behavior (3 & 6 Months)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Real-Time Support for Exercise Persistence in COPD
Brief Summary: The purpose of this exploratory study is to determine the feasibility, acceptability, and efficacy of an exercise persistence intervention for patients with chronic obstructive pulmonary disease (COPD) following pulmonary rehabilitation (PR).


Options:
A: Exercise behavior (3 & 6 Months)
B: Steps per day as mean over one week from baseline until the treatment end (Every day for 6 months)
C: Feasibility of tai chi intervention (24 weeks)
D: Number of exacerbations (12 months)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Strategy Phase III Intergroup Study for Chemotherapy of the Metastatic or Locally Advanced Cancers of the Stomach
Brief Summary: The purpose of this study is to compare the effectiveness of 2 different sequences of polychemotherapy among carrying patients of a adenocarcinoma of the stomach or cardia locally advanced or metastatic.


Options:
A: Overall survival (every course for first three courses, then every other course)
B: Objective response rate; Safety
C: Time until therapeutic failure : to make pass TET from 15 weeks with ECC in first line to 20 weeks with FOLFIRI in first line (20 weeks)
D: overall survival (median)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: In Vivo Study of Safety, Tolerability and Dosing Effect on SMN mRNA and Protein Levels of Valproic Acid in Patients With Spinal Muscular Atrophy
Brief Summary: This is an open label phase I/II clinical trial to assess safety, tolerability and potential effect on SMN mRNA and protein in vivo of a compound in which preliminary evidence supports a potential effect on SMN levels in vitro.


Options:
A: Percent of Participants Who Achieved Improvement in Motor Milestones as Assessed by Section 2 of the HINE at the Last Visit (Day 1352 or Early Termination)
B: Number of Participants That Experienced One Grade III or Higher Unanticipated, Treatment-related Toxicity That Presents With Clinical Symptoms and Requires Medical Treatment (2 years)
C: Time to death or respiratory intervention (Up to Day 2891)
D: To assess safety and tolerability of VPA in SMA patients greater than 2 years of age

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: In Vivo Study of Safety, Tolerability and Dosing Effect on SMN mRNA and Protein Levels of Valproic Acid in Patients With Spinal Muscular Atrophy
Brief Summary: This is an open label phase I/II clinical trial to assess safety, tolerability and potential effect on SMN mRNA and protein in vivo of a compound in which preliminary evidence supports a potential effect on SMN levels in vitro.


Options:
A: To assess safety and tolerability of VPA in SMA patients greater than 2 years of age
B: Percent of Participants Who Achieved Improvement in Motor Milestones as Assessed by Section 2 of the HINE at the Last Visit (Day 1352 or Early Termination)
C: Number of participants that experience Adverse Events (AEs) and Serious Adverse Events (Up to 88 Days); Number of participants with clinically significant neurological examination abnormalities (Up to 88 Days); Number of participants with clinically significant vital sign abnormalities (Up to 88 Days); Number of participants with clinically significant physical examination abnormalities (Up to 88 Days); Number of participants with clinically significant weight abnormalities (Up to 88 Days); Number of participants with clinically significant laboratory parameters (Up to 88 Days); Number or participants with clinically significant cerbrospinal fluid (CSF) laboratory parameters (Up to 88 Days); Number of participants with clinically significant electrocardiograms (ECGs) abnormalities (Up to 88 Days); Number of participants who use concomitant medications (Up to 88 Days); PK parameters of nusinersen (ISIS 396443): Maximum observed plasma drug concentration (Cmax) (Plasma at 1, 2, 4 and 20 hours after dosing); PK parameters of nusinersen: Time to reach maximum observed concentration (Tmax) (Plasma at 1, 2, 4 and 20 hours after dosing); PK parameters of nusinersen: Area under the plasma concentrations time curve from the time of the intrathecal (IT) dose to the last collected sample (AUCinf) (Plasma at 1, 2, 4 and 20 hours after dosing); PK parameters of nusinersen (ISIS 396443): Apparent terminal elimination half-life (t1/2), if possible (Plasma at 1, 2, 4 and 20 hours after dosing)
D: Number of Participants That Experienced One Grade III or Higher Unanticipated, Treatment-related Toxicity That Presents With Clinical Symptoms and Requires Medical Treatment (2 years)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Proton Pump Inhibitors in Conjunction to Endoscopic Therapy for Bleeding Peptic Ulcers: a Randomized Clinical Trial of High vs Standard Doses
Brief Summary: High intravenous dosage of Proton Pump Inhibitors is not better than standard dosage in bleeding peptic ulcers successfully treated by endoscopic therapy


Options:
A: Rebleeding rates and surgical needs
B: Re-bleeding within 14 days in Patients With Peptic Ulcer Bleeding After Successful Endoscopic Therapy (one year)
C: Re-bleeding rate after endoscopic treatment of bleeding peptic ulcers (30 days after endoscopic therapy)
D: Clinically Significant Rebleeding Within 72 Hours of Continous Infusion of Esomeprazole or Placebo (Within 72 hours)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Efficacy of Pimozide Augmentation for Clozapine Partial Response
Brief Summary: This is a 12 week outpatient study for patients with schizophrenia who are on Clozapine, but continue to experience symptoms. The purpose of this project is to find out if small doses of pimozide (an antipsychotic medication, taken by mouth) will be helpful in reducing symptoms (such as hearing voices, having trouble in organizing your thoughts, lack of interest in life events and social activities), compared to placebo (an inactive substance, "sugar pill"), when added to clozapine in patients with schizophrenia.

The participant will be asked to come in once a week to meet with the research staff and study doctor. The participant will continue to see your regular clinician during this study for all normal appointments. The participant will remain on your current medications throughout the study. During the study you will be randomly selected to be put on a small dose of Pimozide or placebo.


Options:
A: Positive Symptom Item Scores by Week and Treatment Group (Baseline and every two weeks for 16 weeks.)
B: Brief Psychiatric Rating Scale (BPRS) Total Score (Baseline); Brief Psychiatric Rating Scale (BPRS) Total Score (Endpoint (12 weeks)); Scale for the Assessment of Negative Symptoms (SANS) (baseline); Scale for the Assessment of Negative Symptoms (SANS) (Endpoint (12 weeks))
C: Change from baseline in total PANSS score to the end of the double-blind phase.
D: Evaluate effect on patient weight of adjunctive therapy of aripiprazole with clozapine versus clozapine mono-therapy in schizophrenic patients who are not optimally controlled on clozapine.; The mean change from baseline in patient weight at Week 16 (LOCF) will be compared between the 2 groups.

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Improving Blood Pressure Management in Patients With Diabetes: SCRIP-HTN
Brief Summary: About 22% of Canadians have high blood pressure, or hypertension. However, studies have shown that only 1 out of 5 people with hypertension have their blood pressure controlled.

Diabetes is also an important risk factor for heart disease and stroke. About half of people with diabetes also have hypertension - a deadly combination. Studies have shown that only about 1 in 10 people with diabetes have their blood pressure controlled adequately - clearly something needs to be done to improve this.

Heart disease, stroke, hypertension, and diabetes are conditions that occur in the community, so we need to explore innovative solutions that will work in the community. Pharmacists are well-placed in the community to help identify people with diabetes and hypertension. This has worked very well in previous studies in patients with high cholesterol levels. Pharmacists and nurses have complementary skills which, when working as a team, may help identify and better manage hypertension in people with diabetes.

Our main objective is to test whether a community pharmacist and nurse team can improve blood pressure control in people with diabetes and hypertension.


Options:
A: difference in change in systolic BP between the intervention and usual care groups (6 months)
B: Percentage of Participans With A1c<7%, LDL Cholesterol <100mg/dL, Systolic Blood Pressure <130mm Hg and Diastolic Blood Pressure <80 mm Hg (4 months)
C: Multiple CVD risk factor control targets (42 months after randomization)
D: Hemoglobin A1c (Change in Baseline in HbA1c at 6 Months)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Improving Blood Pressure Management in Patients With Diabetes: SCRIP-HTN
Brief Summary: About 22% of Canadians have high blood pressure, or hypertension. However, studies have shown that only 1 out of 5 people with hypertension have their blood pressure controlled.

Diabetes is also an important risk factor for heart disease and stroke. About half of people with diabetes also have hypertension - a deadly combination. Studies have shown that only about 1 in 10 people with diabetes have their blood pressure controlled adequately - clearly something needs to be done to improve this.

Heart disease, stroke, hypertension, and diabetes are conditions that occur in the community, so we need to explore innovative solutions that will work in the community. Pharmacists are well-placed in the community to help identify people with diabetes and hypertension. This has worked very well in previous studies in patients with high cholesterol levels. Pharmacists and nurses have complementary skills which, when working as a team, may help identify and better manage hypertension in people with diabetes.

Our main objective is to test whether a community pharmacist and nurse team can improve blood pressure control in people with diabetes and hypertension.


Options:
A: Adherence to inhaled corticosteroid medication (12 months)
B: difference in change in systolic BP between the intervention and usual care groups (6 months)
C: *change in mean diastolic, systolic, and combined diastolic and systolic BP.; *percent of patients with adequately controlled BP.
D: Rate of adherence (2 months and 6 months)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Improving Blood Pressure Management in Patients With Diabetes: SCRIP-HTN
Brief Summary: About 22% of Canadians have high blood pressure, or hypertension. However, studies have shown that only 1 out of 5 people with hypertension have their blood pressure controlled.

Diabetes is also an important risk factor for heart disease and stroke. About half of people with diabetes also have hypertension - a deadly combination. Studies have shown that only about 1 in 10 people with diabetes have their blood pressure controlled adequately - clearly something needs to be done to improve this.

Heart disease, stroke, hypertension, and diabetes are conditions that occur in the community, so we need to explore innovative solutions that will work in the community. Pharmacists are well-placed in the community to help identify people with diabetes and hypertension. This has worked very well in previous studies in patients with high cholesterol levels. Pharmacists and nurses have complementary skills which, when working as a team, may help identify and better manage hypertension in people with diabetes.

Our main objective is to test whether a community pharmacist and nurse team can improve blood pressure control in people with diabetes and hypertension.


Options:
A: difference in change in systolic BP between the intervention and usual care groups (6 months)
B: Percentage of adherence of opportunities for hand hygiene (march 2008, october 2008, may 2009, november 2009)
C: The proportion of patients starting bisphosphonate treatment within 6 months of fracture (6 months)
D: The primary outcome measure will be the "improvement" of prescribing for efficacious therapies in patients with a chronic cardiovascular disease within six months of the intervention.

Answer: A